Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)

NCT00172120 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00172120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00172120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Lead sponsor
Shire
Phase
Phase 3
Overall status
Completed
Start date
January 10, 2005
Completion date
October 27, 2006
Enrollment
91 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis